Structure Therapeutics (GPCR) Share-based Compensation (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Share-based Compensation of $11.6 million for Q1 2026, up 96.67% year-over-year from $5.9 million in Q1 2025, and up 44.24% quarter-over-quarter from $8.1 million in Q4 2025.
Structure Therapeutics (GPCR) Share-based Compensation (2022 - 2026) Analysis & Trends
Structure Therapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $11.6 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 96.67% year-over-year to $11.6 million; the TTM figure through Mar 2026 stood at $34.7 million (up 612.19% YoY), while the FY2025 annual figure was $75.5 million, up 49.21% from the prior year.
- Share-based Compensation for Q1 2026 stood at $11.6 million, up from $8.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $11.6 million in Q1 2026, with the low at -$11.3 million in Q4 2024.
- The 5-year median for Share-based Compensation is $2.5 million (2023), against an average of $3.1 million.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation jumped 308.55% in 2023, then slumped 636.84% in 2024.
- Structure Therapeutics' Share-based Compensation stood at $623000.0 in 2022, then surged by 236.76% to $2.1 million in 2023, then plunged by 636.84% to -$11.3 million in 2024, then soared by 171.64% to $8.1 million in 2025, then jumped by 44.24% to $11.6 million in 2026.
- Business Quant data shows GPCR's Share-based Compensation at $11.6 million in Q1 2026, $8.1 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.63 Mn |
| Jun 30, 2026 | 12.63 Mn |
| Mar 31, 2026 | 11.64 Mn |
| Mar 31, 2026 | 11.64 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Jun 30, 2025 | 7.51 Mn |
| Jun 30, 2025 | 7.51 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Dec 31, 2024 | -11.26 Mn |
| Dec 31, 2024 | -11.26 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Mar 31, 2024 | 2.74 Mn |